Willing Alison E, Eve David J, Sanberg Paul R
Center of Excellence for Aging and Brain Repair, Department of Neurosurgery, University of South Florida College of Medicine, 12901 Bruce B Downs Blvd, Tampa, FL 33612, USA.
Regen Med. 2007 Jul;2(4):457-64. doi: 10.2217/17460751.2.4.457.
One of the most promising treatments for neurodegenerative diseases appears to be human umbilical cord blood cell transplantation. A variety of studies demonstrate some benefit of this method of treatment in a number of different animal models and case studies. However, before the methodologies and results of these animal studies and case studies can be translated into successful widespread treatments, aspects relating to the immunological properties of the transplanted cells must be considered. In this perspective, we discuss the benefit of the cellular immaturity of these cells with respect to the immune response, and compare cord blood transplantation to blood transfusions, as well as discussing what future studies should entail.
人类脐带血细胞移植似乎是神经退行性疾病最有前景的治疗方法之一。各种研究表明，在许多不同的动物模型和案例研究中，这种治疗方法有一定益处。然而，在这些动物研究和案例研究的方法和结果能够转化为成功的广泛治疗方法之前，必须考虑与移植细胞免疫特性相关的方面。从这个角度出发，我们讨论了这些细胞的细胞不成熟性在免疫反应方面的益处，将脐带血移植与输血进行了比较，并讨论了未来研究应涉及的内容。
